Life sciences and biopharma hedge funds are on a three-month winning streak.
A number of funds posted another round of strong gains in August, a month in which the broad market averages were down sharply. This has boosted hope that the devastating multiyear selloff among fledgling biopharma and other healthcare stocks may have bottomed, and that the stocks and the funds that specialize in investing in them are on the road to recovery.
Since
